+Follow
Marou
No personal profile
92
Follow
13
Followers
0
Topic
0
Badge
Posts
Hot
Marou
2022-01-06
👍
Sorry, the original content has been removed
Marou
2021-12-31
👍
4 Growth Stocks Expected to Skyrocket in 2022, According to Wall Street
Marou
2021-12-31
👍
Sorry, the original content has been removed
Marou
2021-12-26
👍
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4101360019325200","uuid":"4101360019325200","gmtCreate":1638259151774,"gmtModify":1639299306602,"name":"Marou","pinyin":"marou","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":92,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9008623036,"gmtCreate":1641433818767,"gmtModify":1676533615057,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008623036","repostId":"1151974693","repostType":4,"isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003374338,"gmtCreate":1640903748972,"gmtModify":1676533552143,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003374338","repostId":"2194074487","repostType":4,"repost":{"id":"2194074487","pubTimestamp":1640749814,"share":"https://ttm.financial/m/news/2194074487?lang=&edition=fundamental","pubTime":"2021-12-29 11:50","market":"us","language":"en","title":"4 Growth Stocks Expected to Skyrocket in 2022, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2194074487","media":"Motley Fool","summary":"Select analysts and investment banks believe these fast-paced companies can catapult higher by 107% to 240% next year.","content":"<p>In just a few days we'll close the book on what's been another great year for the broad-market indexes. Through the holiday-shortened week, the benchmark <b>S&P 500</b> had hit 68 record-closing highs for the year and was up by 26%.</p>\n<p>Yet, in spite of this above-average performance, select Wall Street analysts and investment banks still see incredible value from a quartet of growth stocks. Based on the high-water price target on Wall Street for each respective company, these four stocks are expected to skyrocket between 107% and 240% in 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4b374767519664b8db44345db4054856\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: Implied upside of 126%</h2>\n<p>It's been a wild ride for telehealth kingpin <b>Teladoc Health</b> (NYSE:TDOC). After more than doubling in 2020 amid the coronavirus pandemic, the virtual visit platform has been more than halved this year. But if analyst Sean Dodge of RBC Capital proves accurate in his estimate, Teladoc could rocket 126% higher to a price target of $215 in 2022.</p>\n<p>While critics would argue that Teladoc's sales growth in 2020 was a flash in the pan, the company's growth prior to the pandemic suggests otherwise. In the six years leading up to the pandemic, it grew sales by an annual average of 74%.</p>\n<p>The fact is that Teladoc is changing the face of personalized care. Its virtual visit platform is more convenient for patients and can allow physicians to keep closer tabs on chronically ill people. This should ultimately result in improved patient outcomes and lower costs for health insurers. This latter is particularly important since it means insurers will promote the use of telemedicine, when applicable.</p>\n<p>Teladoc's supercharged growth also comes on the heels of its acquisition of leading applied health signals company Livongo Health a year ago. Livongo uses artificial intelligence to send tips and nudges to its enrolled members with chronic illnesses, such as diabetes and hypertension. The ability for Teladoc and Livongo to cross-sell should help the company maintain jaw-dropping growth potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Trulieve Cannabis: Implied upside of 169%</h2>\n<p>If there's an industry where Wall Street's price targets are consistently well above where the underlying stocks are currently trading, it's cannabis -- specifically U.S. cannabis. If the prognostication of Cantor Fitzgerald analyst Pablo Zuanic proves correct, marijuana stock <b>Trulieve Cannabis</b> (OTC:TCNNF) could hit $72 in 2022. That represents upside of 169%, relative to where shares closed last week.</p>\n<p>Like most multi-state operators (MSO), Trulieve is letting its retail operations do most of the work. But Trulieve took a different path to growth than most MSOs. Instead of trying to plant its proverbial flag in as many legalized states as possible, Trulieve focused most of its attention on saturating medical marijuana-legal Florida. Less than a week ago, it opened its 112th dispensary in the Sunshine State, which compares to 47 outside of Florida.</p>\n<p>Focusing on a single high-dollar market has its perks. Since Trulieve controls well over a quarter of all statewide dispensaries in Florida, it doesn't have to spend much on marketing. Not having to budget a lot of money to build up its brands has resulted in three consecutive years of profitability for the company.</p>\n<p>The next exciting step for Trulieve is inorganic growth. In October, it closed the biggest deal in U.S. cannabis history by purchasing MSO Harvest Health & Recreation. Harvest has a dominant presence in its home market of Arizona, which legalized adult-use weed in November 2020. With a huge presence in Florida and now other high-dollar markets, Trulieve's shares do appear inexpensive.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/adeabde34f734ed7e50341c423f99b88\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Root: Implied upside of 240%</h2>\n<p>Small-cap stocks are expected to get in on the action, too. Following an abysmal year that's seen shares of insurance company <b>Root</b> (NASDAQ:ROOT) decline by 79%, at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> investment bank is expecting a big rebound. Based on Wall Street's high price target of $11, Root offers upside of 240% in 2022.</p>\n<p>For decades, the auto insurance industry has used an assortment of metrics, such as credit scores, age, and marital status, to determine how much their members should pay each month. Unfortunately, these figures don't actually tell insurance companies how well or poor of a driver someone is. Root is aiming to disrupt this stodgy industry by relying on telematics.</p>\n<p>In simple terms, Root is using highly sensitive equipment found in smartphones to detect G-forces while a driver brakes, accelerates, and turns. Utilizing true driving data, as well as driving trends within a state or region, should allow the company to accurately price policies up front for new members.</p>\n<p>On the downside, Root is a relatively new player, which means it's going to have to spend aggressively to build up its brand (i.e., expect sizable losses to continue). However, initial accident loss ratios have been mostly encouraging. With gross accident period loss ratios coming in below 100% for much of the past two years -- a figure below 100% implies a profitably written policy -- the data suggests a telematics-based approach can be successful.</p>\n<p>Root is a very risky investment, but it does offer incredible reward potential.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/81aa2c60b7ad9fa0ab9c99c53e91fca6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: Implied upside of 107%</h2>\n<p>Wall Street also sees big things happening for Singapore-based company <b>Sea Limited</b> (NYSE:SE), which has been in a precipitous downtrend over the past two months. If the $460 price target from <b>Goldman Sachs </b>analyst Piyush Mubayi is correct, megacap stock Sea could more than double in value next year.</p>\n<p>The lure of Sea Limited is that it has a trio of rapidly growing and diversified operating segments.</p>\n<p>For the moment, the company's digital entertainment division is the only one of the three generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea's mobile game, <i>Free Fire</i>, continues to be a worldwide hit. In the September-ended quarter, 12.8% of its 729 million gamers were paying to play. That's a pay-to-play conversion ratio that's many multiples higher than the industry average.</p>\n<p>Secondly, Sea's nascent digital financial services segment is gaining traction. There are now more than 39 million people using the company's digital wallet services, with payment volume hitting $4.6 billion in the third quarter.</p>\n<p>The third fast-growing segment, and arguably what has investors so excited about Sea, is e-commerce platform Shopee. Shopee is consistently the most-downloaded shopping app in Southeastern Asia, and it's gained plenty of appeal in Brazil. Since it's primarily targeting emerging market countries with burgeoning middle classes, growth is off the scale. The $16.8 billion in gross merchandise value (GMV) on Shopee in Q3 2021 is more than the $10 billion in GMV for all of 2018, just to give you an idea of how quickly this segment is growing.</p>\n<p>While $460 in 2022 might be asking a bit much, upside does seem warranted.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Growth Stocks Expected to Skyrocket in 2022, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Growth Stocks Expected to Skyrocket in 2022, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 11:50 GMT+8 <a href=https://www.fool.com/investing/2021/12/28/4-growth-stocks-skyrocket-in-2022-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In just a few days we'll close the book on what's been another great year for the broad-market indexes. Through the holiday-shortened week, the benchmark S&P 500 had hit 68 record-closing highs for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/28/4-growth-stocks-skyrocket-in-2022-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4167":"医疗保健技术","TDOC":"Teladoc Health Inc.","ROOT":"Root, Inc.","BK4535":"淡马锡持仓","SE":"Sea Ltd","BK4567":"ESG概念","BK4505":"高瓴资本持仓","BK4534":"瑞士信贷持仓","BK4107":"财产与意外伤害保险","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4085":"互动家庭娱乐","BK4554":"元宇宙及AR概念","BK4566":"资本集团","BK4503":"景林资产持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/12/28/4-growth-stocks-skyrocket-in-2022-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194074487","content_text":"In just a few days we'll close the book on what's been another great year for the broad-market indexes. Through the holiday-shortened week, the benchmark S&P 500 had hit 68 record-closing highs for the year and was up by 26%.\nYet, in spite of this above-average performance, select Wall Street analysts and investment banks still see incredible value from a quartet of growth stocks. Based on the high-water price target on Wall Street for each respective company, these four stocks are expected to skyrocket between 107% and 240% in 2022.\nImage source: Getty Images.\nTeladoc Health: Implied upside of 126%\nIt's been a wild ride for telehealth kingpin Teladoc Health (NYSE:TDOC). After more than doubling in 2020 amid the coronavirus pandemic, the virtual visit platform has been more than halved this year. But if analyst Sean Dodge of RBC Capital proves accurate in his estimate, Teladoc could rocket 126% higher to a price target of $215 in 2022.\nWhile critics would argue that Teladoc's sales growth in 2020 was a flash in the pan, the company's growth prior to the pandemic suggests otherwise. In the six years leading up to the pandemic, it grew sales by an annual average of 74%.\nThe fact is that Teladoc is changing the face of personalized care. Its virtual visit platform is more convenient for patients and can allow physicians to keep closer tabs on chronically ill people. This should ultimately result in improved patient outcomes and lower costs for health insurers. This latter is particularly important since it means insurers will promote the use of telemedicine, when applicable.\nTeladoc's supercharged growth also comes on the heels of its acquisition of leading applied health signals company Livongo Health a year ago. Livongo uses artificial intelligence to send tips and nudges to its enrolled members with chronic illnesses, such as diabetes and hypertension. The ability for Teladoc and Livongo to cross-sell should help the company maintain jaw-dropping growth potential.\nImage source: Getty Images.\nTrulieve Cannabis: Implied upside of 169%\nIf there's an industry where Wall Street's price targets are consistently well above where the underlying stocks are currently trading, it's cannabis -- specifically U.S. cannabis. If the prognostication of Cantor Fitzgerald analyst Pablo Zuanic proves correct, marijuana stock Trulieve Cannabis (OTC:TCNNF) could hit $72 in 2022. That represents upside of 169%, relative to where shares closed last week.\nLike most multi-state operators (MSO), Trulieve is letting its retail operations do most of the work. But Trulieve took a different path to growth than most MSOs. Instead of trying to plant its proverbial flag in as many legalized states as possible, Trulieve focused most of its attention on saturating medical marijuana-legal Florida. Less than a week ago, it opened its 112th dispensary in the Sunshine State, which compares to 47 outside of Florida.\nFocusing on a single high-dollar market has its perks. Since Trulieve controls well over a quarter of all statewide dispensaries in Florida, it doesn't have to spend much on marketing. Not having to budget a lot of money to build up its brands has resulted in three consecutive years of profitability for the company.\nThe next exciting step for Trulieve is inorganic growth. In October, it closed the biggest deal in U.S. cannabis history by purchasing MSO Harvest Health & Recreation. Harvest has a dominant presence in its home market of Arizona, which legalized adult-use weed in November 2020. With a huge presence in Florida and now other high-dollar markets, Trulieve's shares do appear inexpensive.\nImage source: Getty Images.\nRoot: Implied upside of 240%\nSmall-cap stocks are expected to get in on the action, too. Following an abysmal year that's seen shares of insurance company Root (NASDAQ:ROOT) decline by 79%, at least one investment bank is expecting a big rebound. Based on Wall Street's high price target of $11, Root offers upside of 240% in 2022.\nFor decades, the auto insurance industry has used an assortment of metrics, such as credit scores, age, and marital status, to determine how much their members should pay each month. Unfortunately, these figures don't actually tell insurance companies how well or poor of a driver someone is. Root is aiming to disrupt this stodgy industry by relying on telematics.\nIn simple terms, Root is using highly sensitive equipment found in smartphones to detect G-forces while a driver brakes, accelerates, and turns. Utilizing true driving data, as well as driving trends within a state or region, should allow the company to accurately price policies up front for new members.\nOn the downside, Root is a relatively new player, which means it's going to have to spend aggressively to build up its brand (i.e., expect sizable losses to continue). However, initial accident loss ratios have been mostly encouraging. With gross accident period loss ratios coming in below 100% for much of the past two years -- a figure below 100% implies a profitably written policy -- the data suggests a telematics-based approach can be successful.\nRoot is a very risky investment, but it does offer incredible reward potential.\nImage source: Getty Images.\nSea Limited: Implied upside of 107%\nWall Street also sees big things happening for Singapore-based company Sea Limited (NYSE:SE), which has been in a precipitous downtrend over the past two months. If the $460 price target from Goldman Sachs analyst Piyush Mubayi is correct, megacap stock Sea could more than double in value next year.\nThe lure of Sea Limited is that it has a trio of rapidly growing and diversified operating segments.\nFor the moment, the company's digital entertainment division is the only one of the three generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea's mobile game, Free Fire, continues to be a worldwide hit. In the September-ended quarter, 12.8% of its 729 million gamers were paying to play. That's a pay-to-play conversion ratio that's many multiples higher than the industry average.\nSecondly, Sea's nascent digital financial services segment is gaining traction. There are now more than 39 million people using the company's digital wallet services, with payment volume hitting $4.6 billion in the third quarter.\nThe third fast-growing segment, and arguably what has investors so excited about Sea, is e-commerce platform Shopee. Shopee is consistently the most-downloaded shopping app in Southeastern Asia, and it's gained plenty of appeal in Brazil. Since it's primarily targeting emerging market countries with burgeoning middle classes, growth is off the scale. The $16.8 billion in gross merchandise value (GMV) on Shopee in Q3 2021 is more than the $10 billion in GMV for all of 2018, just to give you an idea of how quickly this segment is growing.\nWhile $460 in 2022 might be asking a bit much, upside does seem warranted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003374930,"gmtCreate":1640903735950,"gmtModify":1676533551964,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003374930","repostId":"2195453431","repostType":4,"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009363424,"gmtCreate":1640503335582,"gmtModify":1676533523718,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009363424","repostId":"2193173436","repostType":4,"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9003374338,"gmtCreate":1640903748972,"gmtModify":1676533552143,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003374338","repostId":"2194074487","repostType":4,"isVote":1,"tweetType":1,"viewCount":673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009363424,"gmtCreate":1640503335582,"gmtModify":1676533523718,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009363424","repostId":"2193173436","repostType":4,"repost":{"id":"2193173436","pubTimestamp":1640485553,"share":"https://ttm.financial/m/news/2193173436?lang=&edition=fundamental","pubTime":"2021-12-26 10:25","market":"us","language":"en","title":"2 Under-the-Radar Biotech Picks to Buy For The Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193173436","media":"Motley Fool","summary":"These quiet biotechs are tightly focused and practically alone in their markets.","content":"<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest <i>downside</i> potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.</p>\n<p>Both companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.</p>\n<h2>1. Catalyst Pharmaceuticals</h2>\n<p><b>Catalyst Pharmaceuticals</b> (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.</p>\n<p>In the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might <a href=\"https://laohu8.com/S/AONE.U\">one</a> day be able to offer it to every LEMS patient in the world.</p>\n<p>Firdapse was originally licensed by Catalyst as part of a deal with <b>BioMarin Pharmaceutical</b>, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.</p>\n<p>So, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.</p>\n<h2>2. Corcept Therapeutics</h2>\n<p><b>Corcept Therapeutics</b> (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.</p>\n<p>Corcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.</p>\n<p>It's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.</p>\n<p>The company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.</p>\n<p>In the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Under-the-Radar Biotech Picks to Buy For The Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Under-the-Radar Biotech Picks to Buy For The Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:25 GMT+8 <a href=https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","CORT":"Corcept医疗","CPRX":"Catalyst Pharmaceutical Partners","FCF":"第一联邦金融","BK4139":"生物科技","BK4007":"制药","BK4211":"区域性银行"},"source_url":"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193173436","content_text":"It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest downside potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.\nBoth companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.\n1. Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.\nIn the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might one day be able to offer it to every LEMS patient in the world.\nFirdapse was originally licensed by Catalyst as part of a deal with BioMarin Pharmaceutical, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.\nSo, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.\n2. Corcept Therapeutics\nCorcept Therapeutics (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.\nCorcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.\nIt's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.\nThe company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.\nIn the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.","news_type":1},"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003374930,"gmtCreate":1640903735950,"gmtModify":1676533551964,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003374930","repostId":"2195453431","repostType":4,"repost":{"id":"2195453431","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640757621,"share":"https://ttm.financial/m/news/2195453431?lang=&edition=fundamental","pubTime":"2021-12-29 14:00","market":"us","language":"en","title":"China's Didi Plans Hong Kong 'Listing by Introduction', Picks Banks -Sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2195453431","media":"Reuters","summary":"* Listing by introduction doesn't involve raising capital\n* Didi aims to file for Hong Kong listing ","content":"<p>* Listing by introduction doesn't involve raising capital</p>\n<p>* Didi aims to file for Hong Kong listing by end-April - source</p>\n<p>* Didi picks Goldman, two Chinese banks for HK listing - sources</p>\n<p>HONG KONG, Dec 29 (Reuters) - China's ride-hailing giant Didi Global plans to use a mechanism that will allow it to list shares in Hong Kong without raising capital or issuing new stock as it seeks to delist from New York, two people with knowledge of the matter said.</p>\n<p>The Hong Kong mechanism, known as 'listing by introduction', would allow owners of Didi U.S. shares to transfer them to the city's bourse gradually, said the people. They declined to be identified as the plan was not yet public.</p>\n<p>Didi aims to file for the Hong Kong listing by end-April and list by June, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people said.</p>\n<p>The plans are being prepared six months after Didi, sometimes dubbed the Uber Technologies Inc of China, made its debut in New York after raising $4.4 billion in a conventional IPO.</p>\n<p>It said earlier this month that it plans to delist from the U.S. bourse and pursue a Hong Kong listing.</p>\n<p>A spokesperson for Didi, whose apps, in addition to ride-hailing, offer products such as delivery and financial services, did not immediately respond to Reuters request for comment.</p>\n<p>Unlike typical IPOs, companies listing stock by introduction in Hong Kong raise no capital and issue no new shares. The mechanism was popular among companies in the past looking to build a brand in Hong Kong and the rest of Greater China.</p>\n<p>Didi has picked Goldman Sachs , China Merchants Bank International (CMBI), and China Construction Bank International (CCBI) to manage the Hong Kong listing process, said the people.</p>\n<p>Goldman declined to comment, while CMBI, and CCBI did not immediately respond to request for comment.</p>\n<p>Reuters reported this month Didi planned to hire Goldman to work on the Hong Kong listing before embarking on the New York delisting. It had asked the bank to come up with proposals on how a Hong Kong listing and New York delisting would work.</p>\n<p>Goldman was one of the main underwriters of Didi's New York IPO, along with <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> and JPMorgan .</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Didi Plans Hong Kong 'Listing by Introduction', Picks Banks -Sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Didi Plans Hong Kong 'Listing by Introduction', Picks Banks -Sources\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-29 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Listing by introduction doesn't involve raising capital</p>\n<p>* Didi aims to file for Hong Kong listing by end-April - source</p>\n<p>* Didi picks Goldman, two Chinese banks for HK listing - sources</p>\n<p>HONG KONG, Dec 29 (Reuters) - China's ride-hailing giant Didi Global plans to use a mechanism that will allow it to list shares in Hong Kong without raising capital or issuing new stock as it seeks to delist from New York, two people with knowledge of the matter said.</p>\n<p>The Hong Kong mechanism, known as 'listing by introduction', would allow owners of Didi U.S. shares to transfer them to the city's bourse gradually, said the people. They declined to be identified as the plan was not yet public.</p>\n<p>Didi aims to file for the Hong Kong listing by end-April and list by June, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people said.</p>\n<p>The plans are being prepared six months after Didi, sometimes dubbed the Uber Technologies Inc of China, made its debut in New York after raising $4.4 billion in a conventional IPO.</p>\n<p>It said earlier this month that it plans to delist from the U.S. bourse and pursue a Hong Kong listing.</p>\n<p>A spokesperson for Didi, whose apps, in addition to ride-hailing, offer products such as delivery and financial services, did not immediately respond to Reuters request for comment.</p>\n<p>Unlike typical IPOs, companies listing stock by introduction in Hong Kong raise no capital and issue no new shares. The mechanism was popular among companies in the past looking to build a brand in Hong Kong and the rest of Greater China.</p>\n<p>Didi has picked Goldman Sachs , China Merchants Bank International (CMBI), and China Construction Bank International (CCBI) to manage the Hong Kong listing process, said the people.</p>\n<p>Goldman declined to comment, while CMBI, and CCBI did not immediately respond to request for comment.</p>\n<p>Reuters reported this month Didi planned to hire Goldman to work on the Hong Kong listing before embarking on the New York delisting. It had asked the bank to come up with proposals on how a Hong Kong listing and New York delisting would work.</p>\n<p>Goldman was one of the main underwriters of Didi's New York IPO, along with <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> and JPMorgan .</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4526":"热门中概股","BK4503":"景林资产持仓","BK4561":"索罗斯持仓","BK4539":"次新股","BK4550":"红杉资本持仓","BK4536":"外卖概念","BK4022":"陆运","BK4535":"淡马锡持仓","BK4505":"高瓴资本持仓","BK4551":"寇图资本持仓","DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195453431","content_text":"* Listing by introduction doesn't involve raising capital\n* Didi aims to file for Hong Kong listing by end-April - source\n* Didi picks Goldman, two Chinese banks for HK listing - sources\nHONG KONG, Dec 29 (Reuters) - China's ride-hailing giant Didi Global plans to use a mechanism that will allow it to list shares in Hong Kong without raising capital or issuing new stock as it seeks to delist from New York, two people with knowledge of the matter said.\nThe Hong Kong mechanism, known as 'listing by introduction', would allow owners of Didi U.S. shares to transfer them to the city's bourse gradually, said the people. They declined to be identified as the plan was not yet public.\nDidi aims to file for the Hong Kong listing by end-April and list by June, one of the people said.\nThe plans are being prepared six months after Didi, sometimes dubbed the Uber Technologies Inc of China, made its debut in New York after raising $4.4 billion in a conventional IPO.\nIt said earlier this month that it plans to delist from the U.S. bourse and pursue a Hong Kong listing.\nA spokesperson for Didi, whose apps, in addition to ride-hailing, offer products such as delivery and financial services, did not immediately respond to Reuters request for comment.\nUnlike typical IPOs, companies listing stock by introduction in Hong Kong raise no capital and issue no new shares. The mechanism was popular among companies in the past looking to build a brand in Hong Kong and the rest of Greater China.\nDidi has picked Goldman Sachs , China Merchants Bank International (CMBI), and China Construction Bank International (CCBI) to manage the Hong Kong listing process, said the people.\nGoldman declined to comment, while CMBI, and CCBI did not immediately respond to request for comment.\nReuters reported this month Didi planned to hire Goldman to work on the Hong Kong listing before embarking on the New York delisting. It had asked the bank to come up with proposals on how a Hong Kong listing and New York delisting would work.\nGoldman was one of the main underwriters of Didi's New York IPO, along with Morgan Stanley and JPMorgan .","news_type":1},"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008623036,"gmtCreate":1641433818767,"gmtModify":1676533615057,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","crmLevel":3,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4101360019325200","authorIdStr":"4101360019325200"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008623036","repostId":"1151974693","repostType":4,"repost":{"id":"1151974693","pubTimestamp":1641340994,"share":"https://ttm.financial/m/news/1151974693?lang=&edition=fundamental","pubTime":"2022-01-05 08:03","market":"sg","language":"en","title":"Singapore Stock Market May Be Stuck In Neutral On Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1151974693","media":"RTTNews","summary":"The Singapore stock market has moved higher in consecutive trading days, gathering almost 50 points ","content":"<html><head></head><body><p>The Singapore stock market has moved higher in consecutive trading days, gathering almost 50 points or 1.6 percent along the way. The Straits Times Index now sits just above the 3,180-point plateau although it may spin its wheels on Wednesday.</p><p>The global forecast for the Asian markets is mixed to higher, with support from oil stocks tempered by weakness from technology shares. The European markets were up and the U.S. bourses were mixed and the Asian markets figure to split the difference.</p><p>The STI finished sharply higher on Tuesday following gains from the financial shares and industrial issues.</p><p>For the day, the index jumped 46.88 points or 1.50 percent to finish at 3,181.13 after trading between 3,151.80 and 3,182.53. Volume was 1.6 billion shares worth 1.38 billion Singapore dollars. There were 271 gainers and 202 decliners.</p><p>Among the actives, Ascendas REIT gained 0.34 percent, while CapitaLand Integrated Commercial Trust rallied 1.95 percent, City Developments rose 0.15 percent, Comfort DelGro gathered 0.72 percent, DBS Group surged 2.81 percent, Keppel Corp perked 0.58 percent, Mapletree Commercial Trust plummeted 5.21 percent, Mapletree Logistics Trust tumbled 1.06 percent, Oversea-Chinese Banking Corporation soared 2.63 percent, SATS jumped 1.29 percent, SembCorp Industries spiked 2.49 percent, Singapore Airlines strengthened 1.00 percent, Singapore Exchange lost 0.53 percent, Singapore Technologies Engineering advanced 0.53 percent, SingTel added 0.43 percent, United Overseas Bank accelerated 2.30 percent, Wilmar International climbed 1.20 percent and Yangzijiang Shipbuilding, Dairy Farm International, Thai Beverage, Singapore Press Holdings and Genting Singapore were unchanged.</p><p>The lead from Wall Street is mixed as the Dow opened higher and stayed that way, the NASDAQ opened lower and stayed that way and the S&P opened higher but fell into the red.</p><p>The Dow spiked 214.59 points or 0.59 percent to a record 36,799.65, while the NASDAQ tumbled 210.08 points or 1.33 percent to close at 15,622.72 and the S&P 500 eased 3.02 points or 0.06 percent to end at 4,793.54.</p><p>The sharp pullback by NASDAQ reflected substantial weakness among software and biotechnology stocks, while financials fueled the Dow.</p><p>The continued advance by the Dow also came as traders remain optimistic about the economic outlook even as the U.S. reported more than 1 million new Covid cases on Monday. Indications the new Omicron variant causes milder symptoms has led to hopes the recent surge could actually help to accelerate the end of the pandemic.</p><p>Crude oil prices climbed higher on Tuesday after OPEC said it would stick to its plan to raise monthly crude production by 400,000 barrels per day in February. West Texas Intermediate crude oil futures for February ended higher by $0.91 or 1.2 percent at $76.99 a barrel.</p></body></html>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market May Be Stuck In Neutral On Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market May Be Stuck In Neutral On Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 08:03 GMT+8 <a href=https://www.rttnews.com/3252737/singapore-stock-market-may-be-stuck-in-neutral-on-wednesday.aspx><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has moved higher in consecutive trading days, gathering almost 50 points or 1.6 percent along the way. The Straits Times Index now sits just above the 3,180-point plateau ...</p>\n\n<a href=\"https://www.rttnews.com/3252737/singapore-stock-market-may-be-stuck-in-neutral-on-wednesday.aspx\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3252737/singapore-stock-market-may-be-stuck-in-neutral-on-wednesday.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151974693","content_text":"The Singapore stock market has moved higher in consecutive trading days, gathering almost 50 points or 1.6 percent along the way. The Straits Times Index now sits just above the 3,180-point plateau although it may spin its wheels on Wednesday.The global forecast for the Asian markets is mixed to higher, with support from oil stocks tempered by weakness from technology shares. The European markets were up and the U.S. bourses were mixed and the Asian markets figure to split the difference.The STI finished sharply higher on Tuesday following gains from the financial shares and industrial issues.For the day, the index jumped 46.88 points or 1.50 percent to finish at 3,181.13 after trading between 3,151.80 and 3,182.53. Volume was 1.6 billion shares worth 1.38 billion Singapore dollars. There were 271 gainers and 202 decliners.Among the actives, Ascendas REIT gained 0.34 percent, while CapitaLand Integrated Commercial Trust rallied 1.95 percent, City Developments rose 0.15 percent, Comfort DelGro gathered 0.72 percent, DBS Group surged 2.81 percent, Keppel Corp perked 0.58 percent, Mapletree Commercial Trust plummeted 5.21 percent, Mapletree Logistics Trust tumbled 1.06 percent, Oversea-Chinese Banking Corporation soared 2.63 percent, SATS jumped 1.29 percent, SembCorp Industries spiked 2.49 percent, Singapore Airlines strengthened 1.00 percent, Singapore Exchange lost 0.53 percent, Singapore Technologies Engineering advanced 0.53 percent, SingTel added 0.43 percent, United Overseas Bank accelerated 2.30 percent, Wilmar International climbed 1.20 percent and Yangzijiang Shipbuilding, Dairy Farm International, Thai Beverage, Singapore Press Holdings and Genting Singapore were unchanged.The lead from Wall Street is mixed as the Dow opened higher and stayed that way, the NASDAQ opened lower and stayed that way and the S&P opened higher but fell into the red.The Dow spiked 214.59 points or 0.59 percent to a record 36,799.65, while the NASDAQ tumbled 210.08 points or 1.33 percent to close at 15,622.72 and the S&P 500 eased 3.02 points or 0.06 percent to end at 4,793.54.The sharp pullback by NASDAQ reflected substantial weakness among software and biotechnology stocks, while financials fueled the Dow.The continued advance by the Dow also came as traders remain optimistic about the economic outlook even as the U.S. reported more than 1 million new Covid cases on Monday. Indications the new Omicron variant causes milder symptoms has led to hopes the recent surge could actually help to accelerate the end of the pandemic.Crude oil prices climbed higher on Tuesday after OPEC said it would stick to its plan to raise monthly crude production by 400,000 barrels per day in February. West Texas Intermediate crude oil futures for February ended higher by $0.91 or 1.2 percent at $76.99 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
